(Q35906921)

11 August 2017

1 reference

title

Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents (English)

1 reference

11 August 2017

Maria Pia Amato

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

Expert Opinion on Pharmacotherapy

11 August 2017

published in

1 reference

11 August 2017

volume

5

1 reference

11 August 2017

issue

10

1 reference

11 August 2017

page(s)

2115-2126

1 reference

The worldwide prevalence of multiple sclerosis

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2115

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2115

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2115

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2115

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2115

Interferons in relapsing remitting multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2115

The economic cost of multiple sclerosis in Sweden in 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2115

A comprehensive assessment of the cost of multiple sclerosis in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2115

Cost-effectiveness analysis: what is it and how will it influence neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2115

Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2115

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2115

Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2115

Long-term treatment of multiple sclerosis with interferon-beta may be cost effective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2115

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2115

A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2115

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2115

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2115

10.1517/14656566.5.10.2115

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference